1. Market Research
  2. > Cellulite – Pipeline Review, H1 2013

Cellulite – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 44 pages

Cellulite – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Cellulite - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cellulite, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cellulite. Cellulite - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cellulite.
- A review of the Cellulite products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cellulite pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cellulite.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cellulite pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Cellulite - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cellulite Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cellulite 7
Cellulite Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Cellulite Therapeutics - Products under Development by Companies 13
Companies Involved in Cellulite Therapeutics Development 14
Auxilium Pharmaceuticals, Inc. 14
Halozyme Therapeutics 15
Helix BioMedix, Inc. 16
Futura Medical plc. 17
Global Health Ventures Inc. 18
Easton Pharmaceuticals Inc. 19
Cellulite - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
collagenase clostridium histolyticum - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
HTI-501 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
POS-002 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
EP-005 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Cellulite Therapeutics - Drug Profile Updates 31
Cellulite - Product Development Milestones 39
Featured News and Press Releases 39
Jan 31, 2012: Interim Data From Phase I Study Of HTI-501 Support Commencement Of Phase II Portion Of Clinical Trial 39
Jan 26, 2012: Auxilium Announces First Cohort Of Patients Dosed In XIAFLEX Phase Ib Cellulite Study 39
Dec 05, 2011: Futura Medical Develops CRF100 For Cellulite Treatment 40
Sep 28, 2011: Halozyme Begins Clinical Trial With HTI-501 In Women With Edematous Fibrosclerotic Panniculopathy 41
Aug 31, 2011: Auxilium And BioSpecifics Announce Plans To Develop Additional Indications Using XIAFLEX 41
May 19, 2008: Halozyme Therapeutics Presents Pre-Clinical Studies on Dermal Remodeling With HTI-501, a Lysosomal Proteinase 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44



List of Tables

Number of Products Under Development for Cellulite, H1 2013 7
Products under Development for Cellulite - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Mid Clinical Stage Development, H1 2013 10
Comparative Analysis by Early Clinical Stage Development, H1 2013 11
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Auxilium Pharmaceuticals, Inc., H1 2013 14
Halozyme Therapeutics, H1 2013 15
Helix BioMedix, Inc., H1 2013 16
Futura Medical plc., H1 2013 17
Global Health Ventures Inc., H1 2013 18
Easton Pharmaceuticals Inc., H1 2013 19
Assessment by Monotherapy Products, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 24
Cellulite Therapeutics - Drug Profile Updates 31



List of Figures

Number of Products under Development for Cellulite, H1 2013 7
Products under Development for Cellulite - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Mid Clinical Stage Products, H1 2013 10
Early Clinical Stage Products, H1 2013 11
Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 20
Assessment by Route of Administration, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Molecule Type, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.